Chinese Expert Consensus on Immunotherapy for Hepatocellular Carcinoma (2021 Edition).

IF 11.6 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Liver Cancer Pub Date : 2022-12-01 DOI:10.1159/000526038

Yu Yang, Juxian Sun, Mengchao Wu, Wan Yee Lau, Shusen Zheng, Xue-Hao Wang, Xiaoping Chen, Jia Fan, Jiahong Dong, Jianqiang Cai, Minshan Chen, Yongjun Chen, Zhangjun Cheng, Chaoliu Dai, Jianzhen Shan, Cheng-You Du, Chihua Fang, Heping Hu, Zhili Ji, Weidong Jia, Gong Li, Jing Li, Jiangtao Li, Chang Liu, Fubao Liu, Yong Ma, Yilei Mao, Zuoxing Niu, Jie Shen, Jie Shi, Xuetao Shi, Wenjie Song, Hui-Chuan Sun, Guang Tan, Ran Tao, Xiaohu Wang, Tianfu Wen, Liqun Wu, Jinglin Xia, Bang-De Xiang, Maolin Yan, Mingang Ying, Ling Zhang, Xuewen Zhang, Zhao Chong Zeng, Yubao Zhang, Zhiwei Zhang, Jie Zhou, Cuncai Zhou, Jun Zhou, Ledu Zhou, Xinmin Zhou, Ji Zhu, Zhenyu Zhu, Qi Zhang, Qiu Li, Shuqun Cheng

{"title":"Chinese Expert Consensus on Immunotherapy for Hepatocellular Carcinoma (2021 Edition).","authors":"Yu Yang, Juxian Sun, Mengchao Wu, Wan Yee Lau, Shusen Zheng, Xue-Hao Wang, Xiaoping Chen, Jia Fan, Jiahong Dong, Jianqiang Cai, Minshan Chen, Yongjun Chen, Zhangjun Cheng, Chaoliu Dai, Jianzhen Shan, Cheng-You Du, Chihua Fang, Heping Hu, Zhili Ji, Weidong Jia, Gong Li, Jing Li, Jiangtao Li, Chang Liu, Fubao Liu, Yong Ma, Yilei Mao, Zuoxing Niu, Jie Shen, Jie Shi, Xuetao Shi, Wenjie Song, Hui-Chuan Sun, Guang Tan, Ran Tao, Xiaohu Wang, Tianfu Wen, Liqun Wu, Jinglin Xia, Bang-De Xiang, Maolin Yan, Mingang Ying, Ling Zhang, Xuewen Zhang, Zhao Chong Zeng, Yubao Zhang, Zhiwei Zhang, Jie Zhou, Cuncai Zhou, Jun Zhou, Ledu Zhou, Xinmin Zhou, Ji Zhu, Zhenyu Zhu, Qi Zhang, Qiu Li, Shuqun Cheng","doi":"10.1159/000526038","DOIUrl":null,"url":null,"abstract":"Background: Hepatocellular carcinoma (HCC) is one of the most common malignancies in China. Most HCC patients are first diagnosed at an advanced stage, and systemic treatments are the mainstay of treatment.Summary: In recent years, immune checkpoint inhibitors have made a breakthrough in the systemic treatment of middle-advanced HCC, breaking the single therapeutic pattern of molecular-targeted agents. To better guide the clinical treatment for effective and safe use of immunotherapeutic drugs, the Chinese Association of Liver Cancer and Chinese Medical Doctor Association has gathered multidisciplinary experts and scholars in relevant fields to formulate the \"Chinese Clinical Expert Consensus on Immunotherapy for Hepatocellular Carcinoma (2021)\" based on current clinical studies and clinical medication experience for reference in China.Key messages: The consensus contained 17 recommendations, including the preferred regimen for first- and second-line immunotherapy, evaluation and monitoring before/during/after treatment, management of complications, precautions for special patients, and potential population for immunotherapy.","PeriodicalId":18156,"journal":{"name":"Liver Cancer","volume":"11 6","pages":"511-526"},"PeriodicalIF":11.6000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/09/02/lic-0011-0511.PMC9801175.pdf","citationCount":"9","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Liver Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000526038","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 9

Abstract

Background: Hepatocellular carcinoma (HCC) is one of the most common malignancies in China. Most HCC patients are first diagnosed at an advanced stage, and systemic treatments are the mainstay of treatment.

Summary: In recent years, immune checkpoint inhibitors have made a breakthrough in the systemic treatment of middle-advanced HCC, breaking the single therapeutic pattern of molecular-targeted agents. To better guide the clinical treatment for effective and safe use of immunotherapeutic drugs, the Chinese Association of Liver Cancer and Chinese Medical Doctor Association has gathered multidisciplinary experts and scholars in relevant fields to formulate the "Chinese Clinical Expert Consensus on Immunotherapy for Hepatocellular Carcinoma (2021)" based on current clinical studies and clinical medication experience for reference in China.

Key messages: The consensus contained 17 recommendations, including the preferred regimen for first- and second-line immunotherapy, evaluation and monitoring before/during/after treatment, management of complications, precautions for special patients, and potential population for immunotherapy.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

中国肝癌免疫治疗专家共识(2021年版)。

背景:肝细胞癌(HCC)是中国最常见的恶性肿瘤之一。大多数HCC患者在晚期才被诊断出来，全身治疗是治疗的主要手段。摘要:近年来，免疫检查点抑制剂在中晚期肝癌的全身治疗中取得突破，打破了分子靶向药物单一的治疗模式。为更好地指导临床治疗，有效、安全地使用免疫治疗药物，中国肝癌协会、中国医师协会联合相关领域多学科专家学者，根据目前的临床研究和国内临床用药经验，制定了《中国肝癌免疫治疗临床专家共识(2021)》，以供参考。关键信息:共识包含17项建议，包括一线和二线免疫治疗的首选方案，治疗前/治疗中/治疗后的评估和监测，并发症的处理，特殊患者的注意事项，以及免疫治疗的潜在人群。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Liver Cancer Medicine-Oncology

CiteScore

20.80

自引率

7.20%

发文量

审稿时长

16 weeks

期刊介绍： Liver Cancer is a journal that serves the international community of researchers and clinicians by providing a platform for research results related to the causes, mechanisms, and therapy of liver cancer. It focuses on molecular carcinogenesis, prevention, surveillance, diagnosis, and treatment, including molecular targeted therapy. The journal publishes clinical and translational research in the field of liver cancer in both humans and experimental models. It publishes original and review articles and has an Impact Factor of 13.8. The journal is indexed and abstracted in various platforms including PubMed, PubMed Central, Web of Science, Science Citation Index, Science Citation Index Expanded, Google Scholar, DOAJ, Chemical Abstracts Service, Scopus, Embase, Pathway Studio, and WorldCat.